Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TOS-358 in HR+/HER2- Metastatic Breast Cancer
NCT05683418Phase 1Recruiting
- Sponsor
- Totus Medicines
- Start
- Feb 2023
- Primary completion
- Dec 2027
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 1, open-label trial of TOS-358 in breast cancer (3 arms), sponsored by Totus Medicines. Primary endpoints: Dose-Limiting Toxicities at 21 days and Adverse Events. Started Feb 2023; status: recruiting.
02
Drugs
TOS-358
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT05683418.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05683418.